These findings reveal a new mechanism wherein CAFs induce platinum resistance through the transfer of EV-encapsulated, which modulates XRCC4 SUMOylation in pancreatic cancer cells, emphasizing the potential therapeutic strategy of targeting the circBIRC6/XRCC4 axis in pancreatic cancer. This evidence concerns the gene XRCC4 and familial pancreatic carcinoma.